John Schiel

Schiel Group



Call: (240) 314-6164


  • Postdoctoral Fellowship, National Institute of Standards and Technology (NIST), 2009-2010
  • Ph.D., Chemistry, University of Nebraska, 2009     
  • B.S., Chemistry, University of Nebraska, 2004


Biomanufacturing and characterization of the ever-increasing cadre of complex therapeutics (protein therapeutics, biologics, cell, and gene therapies) are approaching the point at which disruptive technology may be necessary to advance next generation drugs. With each molecular class come new challenges in the elucidation of structure, mechanism of action, stability, and immunogenicity, as well as regulatory considerations that must be addressed to ensure safety and efficacy. Dr. Schiel develops innovative approaches to the production, characterization, and de-risking of innovative next generation biotherapeutics. His research utilizes a wide variety of instrumentation including high-resolution mass spectrometry, one- and two-dimensional, ultrahigh performance liquid chromatography, capillary electrophoresis, and surface plasmon resonance.


NIST Monoclonal Antibody Reference Material 8671 and Related Resources

The NIST Biomanufacturing Program develops measurement science, standards, reference data, and tools to support the development, manufacturing, and regulatory approval of biologic medicines. The NISTmAb IgG1k is a NIST Reference Material (RM 8671). that embodies the quality and characteristics of a biopharmaceutical product, is widely available to the biopharmaceutical community and is an open innovation tool for development and dissemination of results. The NISTmAb is currently being used to develop novel technology platforms for characterization of protein therapeutics including post-translational modifications, glycosylation, and associated structure-function relationships. The NISTmAb concept is being expanded to include reference cell lines expressing non-originator NISTmAb material, a foundational tool in process innovation and development of metrics for assessing next generation biosimilar drugs.

Multi-Attribute Method Mass Spectrometry

Mass spectrometry, including the multi-attribute mass spectrometry method (MAM), has evolved in recent years as a powerful analytical tool for the characterization of biopharmaceutical product quality attributes. Advances in reproducible sample preparation and high-resolution mass spectrometry have paved the way for attribute-specific process development and show promise as a future quality control strategy. Dr. Schiel’s current research in this area focuses on control and

Graphical representation of attribute-specific biosimilarity afforded by MAM

validation, application of detailed LC-MS-based characterization to novel modalities, and implementation in biosimilarity and comparability studies. Exploring the advantages of new peak detection and developing a data processing platform that allows a sequence agnostic search for new and/or changing impurities are areas of particular interest.

Next Generation Biotherapeutics (CAR-T, gene therapy, viral vector-mediated vaccines, oligonucleotide therapies)

Characterization of mAbs has evolved during the past 30 years to include a toolbox of measurements to elucidate identity, quality, and stability. Molecular complexity is magnified significantly with cell and gene therapies, as is the need for high-throughput characterization. Dr. Schiel’s group is pursuing adaptation, targeted innovation, translation, and implementation of separation science and mass spectrometry-based approaches to further the understanding and development of these novel modalities. Ongoing projects include data-independent proteomics of Chimeric antigen receptor T-cells and mass spectrometry-based characterization of viral vectors and other oligonucleotide-based therapeutics.  

Biopharmaceutical Manufacturing Readiness Levels (BRL) - A Shared Vocabulary for Biopharmaceutical Technology Development and Commercialization.
Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study.
Associations Between Sleep Health and Amygdala Reactivity to Negative Facial Expressions in the UK Biobank Cohort.
Interlaboratory Studies Using the NISTmAb to Advance Biopharmaceutical Structural Analytics.
Ligand-Bound Forced Degradation as a Strategy to Generate Functionally Relevant Analytical Challenge Materials for Assessment of CQAs.
A Sensitive and Controlled Data-Independent Acquisition Method for Proteomic Analysis of Cell Therapies.
New Peak Detection Performance Metrics from the MAM Consortium Interlaboratory Study.
Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies.
Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
Heterologous recombinant expression of non-originator NISTmAb.
The NISTmAb Reference Material 8671 lifecycle management and quality plan.
Development of orthogonal NISTmAb size heterogeneity control methods.
Qualification of NISTmAb charge heterogeneity control assays.
Development of an LC-MS/MS peptide mapping protocol for the NISTmAb.
The NISTmAb Reference Material 8671 value assignment, homogeneity, and stability.
Multivariate Analysis of Two-Dimensional 1H, 13C Methyl NMR Spectra of Monoclonal Antibody Therapeutics To Facilitate Assessment of Higher Order Structure.
Comparison of Traditional 2-AB Fluorescence LC-MS/MS and Automated LC-MS for the Comparative Glycan Analysis of Monoclonal Antibodies.
Bioreactor process parameter screening utilizing a Plackett-Burman design for a model monoclonal antibody.
Universal proteolysis and MS(n) for N- and O-glycan branching analysis.
Glycoprotein analysis using mass spectrometry: unraveling the layers of complexity.